Spironolactone inhibits apoptosis in rat mesangial cells under hyperglycaemic conditions via the Wnt signalling pathway

Molecular and Cellular Biochemistry

Volumn 380, Issue 1-2, 2013, Pages 185-193

  Zhu, Dan ^a   Yu, Hongwei ^b   He, Hongjiang ^b   Ding, Jiuli ^c   Tang, Jie ^a   Cao, Dan ^a   Hao, Lirong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Heilongjiang Power Hospital   (China)

Author keywords

Apoptosis; GSK 3 ; Mesangial cells; Spironolactone; Wnt signalling

Indexed keywords

ALDOSTERONE; BETA CATENIN; CASPASE 3; GLUCOSE; LITHIUM CHLORIDE; SPIRONOLACTONE; WNT PROTEIN; WNT4 PROTEIN; WNT5A PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HYPERGLYCEMIA; MESANGIUM CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STAINING; UPREGULATION;

ALDOSTERONE; ANIMALS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CASPASE 3; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CHLORIDE; MESANGIAL CELLS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPIRONOLACTONE; WNT PROTEINS; WNT SIGNALING PATHWAY; WNT4 PROTEIN;

RATTUS;

EID: 84879797410     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1672-0     Document Type: Article

References (34)

1. Ritz E, Rychlik I, Locatelli F, Halimi S (1999) End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 34:795-808. doi: 10.1016/S0272-6386(99)70035-1
2. Dalla Vestra M, Saller A, Mauer M, Fioretto P (2001) Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol 14(Suppl 4):S51-S57
3. Kitamura H, Shimizu A, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N (1998) Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant-kidney model. Exp Nephrol 6:328-336
4. Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N (1996) Apoptosis in progressive crescentic glomerulonephritis. Lab Invest 74:941-951
5. Mishra R, Emancipator SN, Kern T, Simonson MS (2005) High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int 67:82-93. doi: 10.1111/j.1523-1755.2005.00058.x
6. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota A (1996) Apoptosis in glomerular sclerosis. Kidney Int 49:103-111
7. Pesce C, Menini S, Pricci F, Favre A, Leto G, DiMario U, Pugliese G (2002) Glomerular cell replication and cell loss through apoptosis in experimental diabetes mellitus. Nephron 90:484-488. doi: 54738
8. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J (1994) Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 94:2105-2116. doi: 10.1172/JCI117565
9. Boldyreff B, Wehling M (2003) Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Nephrol Dial Transplant 18:1693-1695
10. Brilla CG, Matsubara LS, Weber KT (1993) Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25:563-575. doi: 10.1006/jmcc.1993.1066
11. Chrysostomou A, Becker G (2001) Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345:925-926. doi: 10.1056/NEJM200109203451215
12. Lai L, Chen J, Hao CM, Lin S, Gu Y (2006) Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1 pathway in mesangial cells. Biochem Biophys Res Commun 348:70-75. doi: 10.1016/j.bbrc.2006.07.057
13. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F, Abe Y (2005) Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45:710-716. doi: 10.1161/01.HYP.0000154681.38944.9a
14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709-717. doi: 10.1056/NEJM199909023411001
15. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S (2004) Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66:1493-1502. doi: 10.1111/j.1523-1755.2004.00913.x
16. Yuan J, Jia R, Bao Y (2007) Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst 8:118-126. doi: 10.3317/jraas.2007.014
17. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK (2006) Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147:5363-5373. doi: 10.1210/en.2006-0944
18. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR (2006) Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70:111-120. doi: 10.1038/sj.ki.5000438
19. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR (2006) Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17:1362-1372. doi: 10.1681/ASN.2005111196
20. Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA (2007) Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292:F131-F139. doi: 10.1152/ajprenal.00147.2006
21. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L (2001) Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 133:687-694. doi: 10.1038/sj.bjp.0704131
22. Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K, Wang FS (2006) Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 17:2812-2820. doi: 10.1681/ASN.2005121355
23. Zhu Dan, Hongjiang H, Hao L, Tang J, Cao D (2012) Aldosterone induces apoptosis via the Wnt signalling pathway. Afr J Pharmacy Pharmacol 6:1428-1434. doi: 10.5897/AJPP12.299
24. Wang FS, Lin CL, Chen YJ, Wang CJ, Yang KD, Huang YT, Sun YC, Huang HC (2005) Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 146:2415-2423. doi: 10.1210/en.2004-1050
25. Salvesen GS, Dixit VM (1997) Caspases: intracellular signaling by proteolysis. Cell 91:443-446
26. Rehm M, Dussmann H, Janicke RU, Tavare JM, Kogel D, Prehn JH (2002) Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process. Role of caspase-3. J Biol Chem 277:24506-24514. doi: 10.1074/jbc.M110789200
27. Chen C, Liang W, Jia J, van Goor H, Singhal PC, Ding G (2009) Aldosterone induces apoptosis in rat podocytes: role of PI3-K/Akt and p38MAPK signaling pathways. Nephron Exp Nephrol 113:e26-e34. doi: 10.1159/000228080
28. Merkel CE, Karner CM, Carroll TJ (2007) Molecular regulation of kidney development: is the answer blowing in the Wnt? Pediatr Nephrol 22:1825-1838. doi: 10.1007/s00467-007-0504-4
29. Bridgewater D, Di Giovanni V, Cain JE, Cox B, Jakobson M, Sainio K, Rosenblum ND (2011) Beta-catenin causes renal dysplasia via upregulation of Tgfbeta2 and Dkk1. J Am Soc Nephrol 22:718-731. doi: 10.1681/ASN.2010050562
30. Vinas JL, Sola A, Jung M, Mastora C, Vinuesa E, Pi F, Hotter G (2010) Inhibitory action of Wnt target gene osteopontin on mitochondrial cytochrome c release determines renal ischemic resistance. Am J Physiol Renal Physiol 299:F234-F242. doi: 10.1152/ajprenal.00687.2009
31. Zeilstra J, Joosten SP, Wensveen FM, Dessing MC, Schutze DM, Eldering E, Spaargaren M, Pals ST (2011) WNT signaling controls expression of pro-apoptotic BOK and BAX in intestinal cancer. Biochem Biophys Res Commun 406:1-6. doi: 10.1016/j.bbrc.2010.12.070
32. Pecina-Slaus N (2010) Wnt signal transduction pathway and apoptosis: a review. Cancer Cell Int 10:22. doi: 10.1186/1475-2867-10-22
33. Turashvili G, Bouchal J, Burkadze G, Kolar Z (2006) Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73:213-223. doi: 10.1159/000098207
34. Lian M, Hewitson TD, Wigg B, Samuel CS, Chow F, Becker GJ (2012) Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol Dial Transplant 27:906-912. doi: 10.1093/ndt/gfr495